Carisma Therapeutics, Inc. (W2J.F)

1,3730 -0,0200 (-1,44%) Börsenschluss: 03:29PM CEST

Carisma Therapeutics, Inc.

3675 Market Street
Suite 200
Philadelphia, PA 19104
United States
267-491-6422
https://www.carismatx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 107

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Steven Kelly	President, CEO & Director	729,56k	N/A	1965
Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD	Co-Founder & Chief Scientific Officer	487,14k	N/A	1990
Mr. Richard S. Morris CPA	CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off.	542,23k	N/A	1974
Dr. Saar Gill M.D., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Dr. Daniel J. Cushing FCP, Ph.D.	Chief Technology & Development Officer	N/A	N/A	N/A
Mr. Eric H. Siegel J.D., MBA	General Counsel & Corporate Secretary	N/A	N/A	1965
Ms. Terry Shields	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Tom Wilton	Chief Business Officer	N/A	N/A	1974
Dr. Eugene P. Kennedy F.A.C.S., M.D.	Chief Medical Officer	N/A	N/A	1969

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Carisma Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 10, Vorstand: 7, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.